* Develop and lead integrated biomarker strategies across oncology and hematology programs, in partnership with cross-functional development teams.
* Translate disease biology and therapeutic mechanism into clear translational hypotheses and fit-for-purpose biomarker approaches.
* Define how biomarkers can inform key development questions including proof of biology, target engagement, dose and regimen selection, patient selection, response assessment, resistance mechanisms, and go/no-go decisions.
* Ensure biomarker strategies are focused and scalable, with clear linkage between the development question, proposed measurement, expected result, and potential action.
* Serve as the biomarker representative on cross-functional program teams and provide strategic biomarker input to program-level decision making.
* Partner closely with Discovery, Clinical Development, Quantitative Sciences, Regulatory, Data Science, Clinical Operations, Pathology, Diagnostics, and other functions to develop integrated translational strategies.
* Lead interpretation of biomarker and clinical datasets and translate complex findings into clear, actionable recommendations.
* Develop approaches to characterize disease heterogeneity, molecular drivers, treatment response, mechanisms of resistance, and biological determinants of clinical outcome.
* Develop and evaluate patient-selection and precision-medicine strategies, including approaches based on genomic, transcriptomic, protein-expression, cellular, or other disease-specific biomarkers.
* Apply circulating and tissue-based biomarker approaches, as appropriate, including ctDNA, minimal residual disease, molecular profiling, immunophenotyping, and pharmacodynamic biomarkers.
* For hematologic malignancies, develop strategies incorporating disease-relevant measures such as molecular response, measurable residual disease, clonal evolution, mutational burden, lineage or cellular phenotype, and resistance-associated alterations, as appropriate to the program.
* For solid tumors, develop strategies addressing target expression, tumor biology, molecular subtype, immune contexture, circulating biomarkers, mechanisms of response and resistance, and potential predictive biomarkers.
* Evaluate emerging biomarker technologies and analytical approaches based on their ability to address meaningful development questions and influence program decisions.
* Contribute to biomarker strategies supporting potential companion diagnostic or regulatory biomarker development, where appropriate.
* Communicate biomarker strategies, results, risks, and recommendations clearly to cross-functional teams, governance groups, and key stakeholders.
* Provide scientific guidance and mentorship to biomarker scientists and contribute to a collaborative, strategically focused biomarker organization.
* Support publications, scientific presentations, external collaborations, and interactions with key external experts as appropriate.